177 Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer

Finn E. von Eyben; Timo Kiljunen; Timo Joensuu; Kalevi Kairemo; Christian Uprimny; Irene Virgolini

doi:10.18632/oncotarget.19805

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

¹⁷⁷Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer

Finn E. von Eyben _, Timo Kiljunen, Timo Joensuu, Kalevi Kairemo, Christian Uprimny and Irene Virgolini

PDF | HTML | How to cite

Oncotarget. 2017; 8:66112-66116. https://doi.org/10.18632/oncotarget.19805

Metrics: PDF 1690 views | HTML 2833 views | ?

Abstract

Finn E. von Eyben1, Timo Kiljunen2, Timo Joensuu2, Kalevi Kairemo2, Christian Uprimny3 and Irene Virgolini3

1Center of Tobacco Control Research, Odense, Denmark

2Docrates Cancer Center, Helsinki, Finland

3Department of Nuclear Medicine, Innsbruck University Hospital, Innsbruck, Austria

Correspondence to:

Finn E. von Eyben, email: [email protected]

Keywords: abiraterone, cross-over study, external beam radiotherapy, lutetium radiolabled prostate membrane specific antigen radioligand therapy, metastatic prostate cancer

Received: May 12, 2017 Accepted: July 11, 2017 Published: August 02, 2017

ABSTRACT

Prostate specific membrane antigen (PSMA) is expressed in unfavorable prostate cancer. PSMA is basis for new diagnostics and theranostics. PET/CT using PSMA is more sensitive than choline PET/CT. ¹⁷⁷Lu-PSMA radioligand therapy is mainly used for patients with end-stage prostate cancer. This report describes a patient with a third recurrence in lymph nodes. The recurrence was treated with ¹⁷⁷Lu-PSMA radioligand therapy instead of chemotherapy with docetaxel. The effect was in part evaluated relative to that of two established salvage treatments. Prior salvage radiotherapy and abiraterone of the first and second recurrence in lymph nodes had given only a partial reduction of PSA. Nevertheless within five months of follow-up, ¹⁷⁷Lu-PSMA radioligand therapy of the third recurrence in lymph nodes reduced PSA for a period to unmeasurable levels. ¹⁷⁷Lu-PSMA radioligand therapy gave only mild adverse effects. In conclusion, for a patient with lymph node metastatic prostate cancer, ¹⁷⁷Lu-PSMA-617 radioligand therapy had an attractive therapeutic profile. A follow-up study of similar patients is being planned.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19805

Publication Alerts

Research Papers:

177Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer

Abstract

¹⁷⁷Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer